GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Q BioMed Inc (OTCPK:QBIO) » Definitions » Earnings per Share (Diluted)

Q BioMed (Q BioMed) Earnings per Share (Diluted) : $-0.08 (TTM As of Feb. 2023)


View and export this data going back to 2014. Start your Free Trial

What is Q BioMed Earnings per Share (Diluted)?

Q BioMed's Earnings per Share (Diluted) for the three months ended in Feb. 2023 was $-0.02. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Feb. 2023 was $-0.08.

Q BioMed's EPS (Basic) for the three months ended in Feb. 2023 was $-0.02. Its EPS (Basic) for the trailing twelve months (TTM) ended in Feb. 2023 was $-0.08.

Q BioMed's EPS without NRI for the three months ended in Feb. 2023 was $-0.02. Its EPS without NRI for the trailing twelve months (TTM) ended in Feb. 2023 was $-0.09.


Q BioMed Earnings per Share (Diluted) Historical Data

The historical data trend for Q BioMed's Earnings per Share (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Q BioMed Earnings per Share (Diluted) Chart

Q BioMed Annual Data
Trend Nov13 Nov14 Nov15 Nov16 Nov17 Nov18 Nov19 Nov20 Nov21 Nov22
Earnings per Share (Diluted)
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.67 -0.68 -0.65 -0.33 -0.08

Q BioMed Quarterly Data
May18 Aug18 Nov18 Feb19 May19 Aug19 Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23
Earnings per Share (Diluted) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.08 -0.06 -0.03 0.03 -0.02

Competitive Comparison of Q BioMed's Earnings per Share (Diluted)

For the Biotechnology subindustry, Q BioMed's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Q BioMed's PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Q BioMed's PE Ratio distribution charts can be found below:

* The bar in red indicates where Q BioMed's PE Ratio falls into.



Q BioMed Earnings per Share (Diluted) Calculation

Earnings Per Share (EPS) is the amount of earnings per outstanding share of the company's stock. In calculating earnings per share, the dividends of preferred stocks need to subtracted from the total net income first.

Q BioMed's Earnings Per Share (Diluted) for the fiscal year that ended in Nov. 2022 is calculated as

Diluted Earnings Per Share (A: Nov. 2022 ) = (Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-2.052-1.442)/44.757
=-0.08

Q BioMed's Earnings Per Share (Diluted) for the quarter that ended in Feb. 2023 is calculated as

Diluted Earnings Per Share (Q: Feb. 2023 )=(Net Income - Preferred Dividends / Shares Outstanding (Diluted Average)
=(-0.722-0.105)/108.730
=-0.01

Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Feb. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.08

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies also reported diluted shares in their financial reports. Diluted shares include the shares of convertibles or warrants outstanding.


Q BioMed  (OTCPK:QBIO) Earnings per Share (Diluted) Explanation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Q BioMed Earnings per Share (Diluted) Related Terms

Thank you for viewing the detailed overview of Q BioMed's Earnings per Share (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.


Q BioMed (Q BioMed) Business Description

Industry
Traded in Other Exchanges
N/A
Address
C/o Ortoli Rosenstadt LLP, 366 Madison Avenue, 3rd Floor, New York, NY, USA, 10017
Q BioMed Inc is a biomedical acceleration and development company. It has a focus on licensing, acquiring, and providing strategic resources to life sciences and healthcare companies. The company intends to mitigate risk by acquiring multiple assets over time and across a broad spectrum of healthcare-related products, companies, and sectors. Generic Strontium Chloride Sr-89 Injection USP (Strontium-89) is a radioactive pharmaceutical injection to relieve bone pain in patients with painful skeletal metastases. It also has three development-stage products: QBM-001 for rare pediatric non-verbal autism spectrum disorder, Uttroside-B for liver cancer, and MAN 01 for glaucoma.
Executives
William S Rosenstadt director, 10 percent owner, officer: Chief Legal Officer ORTOLI ROSENSTADT LLP, 501 MADISON AVENUE, 14TH FLOOR, NEW YORK NY 10022
Denis Corin director, 10 percent owner, officer: Chief Executive Officer 10 MARKET STREET, SUITE 427, GRAND CAYMAN E9 KY1-9006
Rick Panicucci director 501 MADISON STREET, 14TH FLOOR, NEW YORK NY 10022
Alan P Lindsay 10 percent owner 580 HORNBY STREET, FIFTH FLOOR, VANCOUVER BC CANADA V6C 2E7 A1